Abeona Therapeutics Inc Q2 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Congrats on the progress, especially in light of everything that's going on. So the first question. As it relates to EB-101, you discussed a potential commercial launch in late 2022. Could you talk about how much time you might need to prepare for a launch after a potential approval? I guess what I'm trying to calculate is that given your rare pediatric disease designation, whether this approval could come before September 30, 2022, when you could potentially receive a voucher pending FDA time lines of course.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Okay. Great. So I understand you're doing the preparations now, but I guess the question was more targeted towards once you have an actual approval in hand, how long that time line could take? And whether or not you think you could potentially get this approval ahead of this aspiration for rare pediatric disease designation vouchers?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : That's very helpful. And then for the MPS IIIA study, you've indicated that Cohort 3 could treat anywhere between 9 to 16 subjects. And for MPS IIIB, that could be up to 5 patients for Cohort 3. So just given that you've provided guidance today in terms of completing enrollment by the end of the year, could you discuss whether there's a specific patient number that you're targeting for each of these groups?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Okay. Great. And then the last question for me is that I recognize meeting you had with the EMA related to ABO-102. But do you think the proposed outline could be similar to ABO-101? And are you thinking about any synergies across the 2 programs, given 1 or 2 is a little bit more advanced?